Treatment of CLL cells with the cell-permeable phospho-peptide EGQY*EEIP has been shown to preferentially bind the SH2 domain of Lck vs Lyn due to the specificity of the YEEI sequence, which prevents activation of Lck’s catalytic domain (21). The gene discussed is LYN; the disease is B-cell chronic lymphocytic leukemia.